Premium
Intra‐arterial methotrexate chemotherapy and telecobalt therapy in cancer of the oral cavity and oropharynx
Author(s) -
Richard J. M.,
Sancho H.,
Lepintre Y.,
Rodary J.,
Pierquin B.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197409)34:3<491::aid-cncr2820340303>3.0.co;2-g
Subject(s) - medicine , radiation therapy , chemotherapy , oral cavity , methotrexate , cancer , oncology , surgery , dentistry
This paper presents the results of a controlled therapeutic trial comparing the combination of intra‐arterial infusion chemotherapy and radiotherapy with radiotherapy alone in advanced (T4) cancers of the oral cavity and oropharynx. Tumor regression was far greater with the combination treatment: 40% compared to 10% with radiotherapy alone. The median survival rate was 6 months in the group receiving radiotherapy alone, and 9 months in those receiving the combination. While recognizing the importance of the treatment, the authors realize the necessity of continued investigation into different combination possibilities in order to obtain better survival results.